

Global Peripheral T-cell lymphoma Therapy Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G0D359A5AA67EN.html>

Date: January 2023

Pages: 112

Price: US\$ 4,480.00 (Single User License)

ID: G0D359A5AA67EN

Abstracts

This report studies the global Peripheral T-cell lymphoma Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Peripheral T-cell lymphoma Therapy, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peripheral T-cell lymphoma Therapy that contribute to its increasing demand across many markets.

The global Peripheral T-cell lymphoma Therapy market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Highlights and key features of the study

Global Peripheral T-cell lymphoma Therapy total market, 2018-2029, (USD Million)

Global Peripheral T-cell lymphoma Therapy total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Peripheral T-cell lymphoma Therapy total market, key domestic companies and share, (USD Million)

Global Peripheral T-cell lymphoma Therapy revenue by player and market share 2018-2023, (USD Million)

Global Peripheral T-cell lymphoma Therapy total market by Type, CAGR, 2018-2029, (USD Million)

Global Peripheral T-cell lymphoma Therapy total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Peripheral T-cell lymphoma Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Antengene, Genor BioPharma Co., Ltd., Hospira (Pfizer Inc.), Dizal Pharma, Bristol-Myers Squibb Company, Sigma-Tau Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc. and Celgene Corporation, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Peripheral T-cell lymphoma Therapy market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Peripheral T-cell lymphoma Therapy Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Peripheral T-cell lymphoma Therapy Market, Segmentation by Type

Chidamide

Selinexor

Other

Global Peripheral T-cell lymphoma Therapy Market, Segmentation by Application

Hospitals

Clinics

Companies Profiled:

Antengene

Genor BioPharma Co., Ltd.

Hospira (Pfizer Inc.)

Dizal Pharma

Bristol-Myers Squibb Company

Sigma-Tau Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Celgene Corporation

Eisai Co., Ltd.

Leadiant Biosciences

Merck

Genmab AS

HUYABIO International

Key Questions Answered

1. How big is the global Peripheral T-cell lymphoma Therapy market?
2. What is the demand of the global Peripheral T-cell lymphoma Therapy market?
3. What is the year over year growth of the global Peripheral T-cell lymphoma Therapy market?
4. What is the total value of the global Peripheral T-cell lymphoma Therapy market?
5. Who are the major players in the global Peripheral T-cell lymphoma Therapy market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 Peripheral T-cell lymphoma Therapy Introduction
- 1.2 World Peripheral T-cell lymphoma Therapy Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Peripheral T-cell lymphoma Therapy Total Market by Region (by Headquarter Location)
 - 1.3.1 World Peripheral T-cell lymphoma Therapy Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.3 China Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.4 Europe Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.5 Japan Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.6 South Korea Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.7 ASEAN Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
 - 1.3.8 India Peripheral T-cell lymphoma Therapy Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Peripheral T-cell lymphoma Therapy Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Peripheral T-cell lymphoma Therapy Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
 - 1.5.1 Influence of COVID-19
 - 1.5.2 Influence of Russia-Ukraine War

2 DEMAND SUMMARY

- 2.1 World Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)
- 2.2 World Peripheral T-cell lymphoma Therapy Consumption Value by Region
 - 2.2.1 World Peripheral T-cell lymphoma Therapy Consumption Value by Region (2018-2023)
 - 2.2.2 World Peripheral T-cell lymphoma Therapy Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)
- 2.4 China Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)
- 2.5 Europe Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)
- 2.6 Japan Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)
- 2.7 South Korea Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)

2.8 ASEAN Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)

2.9 India Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029)

3 WORLD PERIPHERAL T-CELL LYMPHOMA THERAPY COMPANIES COMPETITIVE ANALYSIS

3.1 World Peripheral T-cell lymphoma Therapy Revenue by Player (2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Peripheral T-cell lymphoma Therapy Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Peripheral T-cell lymphoma Therapy in 2022

3.2.3 Global Concentration Ratios (CR8) for Peripheral T-cell lymphoma Therapy in 2022

3.3 Peripheral T-cell lymphoma Therapy Company Evaluation Quadrant

3.4 Peripheral T-cell lymphoma Therapy Market: Overall Company Footprint Analysis

3.4.1 Peripheral T-cell lymphoma Therapy Market: Region Footprint

3.4.2 Peripheral T-cell lymphoma Therapy Market: Company Product Type Footprint

3.4.3 Peripheral T-cell lymphoma Therapy Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Peripheral T-cell lymphoma Therapy Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Peripheral T-cell lymphoma Therapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: Peripheral T-cell lymphoma Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: Peripheral T-cell lymphoma Therapy Consumption Value Comparison

4.2.1 United States VS China: Peripheral T-cell lymphoma Therapy Consumption Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Peripheral T-cell lymphoma Therapy Consumption

Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based Peripheral T-cell lymphoma Therapy Companies and Market Share, 2018-2023

4.3.1 United States Based Peripheral T-cell lymphoma Therapy Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023)

4.4 China Based Companies Peripheral T-cell lymphoma Therapy Revenue and Market Share, 2018-2023

4.4.1 China Based Peripheral T-cell lymphoma Therapy Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023)

4.5 Rest of World Based Peripheral T-cell lymphoma Therapy Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Peripheral T-cell lymphoma Therapy Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Peripheral T-cell lymphoma Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Chidamide

5.2.2 Selinexor

5.2.3 Other

5.3 Market Segment by Type

5.3.1 World Peripheral T-cell lymphoma Therapy Market Size by Type (2018-2023)

5.3.2 World Peripheral T-cell lymphoma Therapy Market Size by Type (2024-2029)

5.3.3 World Peripheral T-cell lymphoma Therapy Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Peripheral T-cell lymphoma Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Hospitals

6.2.2 Clinics

6.3 Market Segment by Application

6.3.1 World Peripheral T-cell lymphoma Therapy Market Size by Application (2018-2023)

6.3.2 World Peripheral T-cell lymphoma Therapy Market Size by Application (2024-2029)

6.3.3 World Peripheral T-cell lymphoma Therapy Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Antengene

7.1.1 Antengene Details

7.1.2 Antengene Major Business

7.1.3 Antengene Peripheral T-cell lymphoma Therapy Product and Services

7.1.4 Antengene Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Antengene Recent Developments/Updates

7.1.6 Antengene Competitive Strengths & Weaknesses

7.2 Genor BioPharma Co., Ltd.

7.2.1 Genor BioPharma Co., Ltd. Details

7.2.2 Genor BioPharma Co., Ltd. Major Business

7.2.3 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product and Services

7.2.4 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Genor BioPharma Co., Ltd. Recent Developments/Updates

7.2.6 Genor BioPharma Co., Ltd. Competitive Strengths & Weaknesses

7.3 Hospira (Pfizer Inc.)

7.3.1 Hospira (Pfizer Inc.) Details

7.3.2 Hospira (Pfizer Inc.) Major Business

7.3.3 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product and Services

7.3.4 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Hospira (Pfizer Inc.) Recent Developments/Updates

7.3.6 Hospira (Pfizer Inc.) Competitive Strengths & Weaknesses

7.4 Dizal Pharma

7.4.1 Dizal Pharma Details

- 7.4.2 Dizal Pharma Major Business
- 7.4.3 Dizal Pharma Peripheral T-cell lymphoma Therapy Product and Services
- 7.4.4 Dizal Pharma Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 7.4.5 Dizal Pharma Recent Developments/Updates
- 7.4.6 Dizal Pharma Competitive Strengths & Weaknesses
- 7.5 Bristol-Myers Squibb Company
 - 7.5.1 Bristol-Myers Squibb Company Details
 - 7.5.2 Bristol-Myers Squibb Company Major Business
 - 7.5.3 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product and Services
 - 7.5.4 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
 - 7.5.6 Bristol-Myers Squibb Company Competitive Strengths & Weaknesses
- 7.6 Sigma-Tau Pharmaceuticals, Inc.
 - 7.6.1 Sigma-Tau Pharmaceuticals, Inc. Details
 - 7.6.2 Sigma-Tau Pharmaceuticals, Inc. Major Business
 - 7.6.3 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services
 - 7.6.4 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 Sigma-Tau Pharmaceuticals, Inc. Recent Developments/Updates
 - 7.6.6 Sigma-Tau Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
- 7.7 Pacira Pharmaceuticals, Inc.
 - 7.7.1 Pacira Pharmaceuticals, Inc. Details
 - 7.7.2 Pacira Pharmaceuticals, Inc. Major Business
 - 7.7.3 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services
 - 7.7.4 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 Pacira Pharmaceuticals, Inc. Recent Developments/Updates
 - 7.7.6 Pacira Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
- 7.8 Spectrum Pharmaceuticals, Inc.
 - 7.8.1 Spectrum Pharmaceuticals, Inc. Details
 - 7.8.2 Spectrum Pharmaceuticals, Inc. Major Business
 - 7.8.3 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services
 - 7.8.4 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue,

Gross Margin and Market Share (2018-2023)

7.8.5 Spectrum Pharmaceuticals, Inc. Recent Developments/Updates

7.8.6 Spectrum Pharmaceuticals, Inc. Competitive Strengths & Weaknesses

7.9 Celgene Corporation

7.9.1 Celgene Corporation Details

7.9.2 Celgene Corporation Major Business

7.9.3 Celgene Corporation Peripheral T-cell lymphoma Therapy Product and Services

7.9.4 Celgene Corporation Peripheral T-cell lymphoma Therapy Revenue, Gross

Margin and Market Share (2018-2023)

7.9.5 Celgene Corporation Recent Developments/Updates

7.9.6 Celgene Corporation Competitive Strengths & Weaknesses

7.10 Eisai Co., Ltd.

7.10.1 Eisai Co., Ltd. Details

7.10.2 Eisai Co., Ltd. Major Business

7.10.3 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product and Services

7.10.4 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin

and Market Share (2018-2023)

7.10.5 Eisai Co., Ltd. Recent Developments/Updates

7.10.6 Eisai Co., Ltd. Competitive Strengths & Weaknesses

7.11 Leadiant Biosciences

7.11.1 Leadiant Biosciences Details

7.11.2 Leadiant Biosciences Major Business

7.11.3 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product and Services

7.11.4 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.11.5 Leadiant Biosciences Recent Developments/Updates

7.11.6 Leadiant Biosciences Competitive Strengths & Weaknesses

7.12 Merck

7.12.1 Merck Details

7.12.2 Merck Major Business

7.12.3 Merck Peripheral T-cell lymphoma Therapy Product and Services

7.12.4 Merck Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)

7.12.5 Merck Recent Developments/Updates

7.12.6 Merck Competitive Strengths & Weaknesses

7.13 Genmab AS

7.13.1 Genmab AS Details

7.13.2 Genmab AS Major Business

- 7.13.3 Genmab AS Peripheral T-cell lymphoma Therapy Product and Services
- 7.13.4 Genmab AS Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
- 7.13.5 Genmab AS Recent Developments/Updates
- 7.13.6 Genmab AS Competitive Strengths & Weaknesses
- 7.14 HUYABIO International
 - 7.14.1 HUYABIO International Details
 - 7.14.2 HUYABIO International Major Business
 - 7.14.3 HUYABIO International Peripheral T-cell lymphoma Therapy Product and Services
 - 7.14.4 HUYABIO International Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023)
 - 7.14.5 HUYABIO International Recent Developments/Updates
 - 7.14.6 HUYABIO International Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Peripheral T-cell lymphoma Therapy Industry Chain
- 8.2 Peripheral T-cell lymphoma Therapy Upstream Analysis
- 8.3 Peripheral T-cell lymphoma Therapy Midstream Analysis
- 8.4 Peripheral T-cell lymphoma Therapy Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Peripheral T-cell lymphoma Therapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Peripheral T-cell lymphoma Therapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Peripheral T-cell lymphoma Therapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Peripheral T-cell lymphoma Therapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Peripheral T-cell lymphoma Therapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Peripheral T-cell lymphoma Therapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Peripheral T-cell lymphoma Therapy Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Peripheral T-cell lymphoma Therapy Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Peripheral T-cell lymphoma Therapy Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Peripheral T-cell lymphoma Therapy Players in 2022

Table 12. World Peripheral T-cell lymphoma Therapy Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Peripheral T-cell lymphoma Therapy Company Evaluation Quadrant

Table 14. Head Office of Key Peripheral T-cell lymphoma Therapy Player

Table 15. Peripheral T-cell lymphoma Therapy Market: Company Product Type Footprint

Table 16. Peripheral T-cell lymphoma Therapy Market: Company Product Application Footprint

Table 17. Peripheral T-cell lymphoma Therapy Mergers & Acquisitions Activity

Table 18. United States VS China Peripheral T-cell lymphoma Therapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Peripheral T-cell lymphoma Therapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Peripheral T-cell lymphoma Therapy Companies,

Headquarters (States, Country)

Table 21. United States Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Peripheral T-cell lymphoma Therapy Revenue Market Share (2018-2023)

Table 23. China Based Peripheral T-cell lymphoma Therapy Companies, Headquarters (Province, Country)

Table 24. China Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Peripheral T-cell lymphoma Therapy Revenue Market Share (2018-2023)

Table 26. Rest of World Based Peripheral T-cell lymphoma Therapy Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Peripheral T-cell lymphoma Therapy Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Peripheral T-cell lymphoma Therapy Revenue Market Share (2018-2023)

Table 29. World Peripheral T-cell lymphoma Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Peripheral T-cell lymphoma Therapy Market Size by Type (2018-2023) & (USD Million)

Table 31. World Peripheral T-cell lymphoma Therapy Market Size by Type (2024-2029) & (USD Million)

Table 32. World Peripheral T-cell lymphoma Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Peripheral T-cell lymphoma Therapy Market Size by Application (2018-2023) & (USD Million)

Table 34. World Peripheral T-cell lymphoma Therapy Market Size by Application (2024-2029) & (USD Million)

Table 35. Antengene Basic Information, Area Served and Competitors

Table 36. Antengene Major Business

Table 37. Antengene Peripheral T-cell lymphoma Therapy Product and Services

Table 38. Antengene Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Antengene Recent Developments/Updates

Table 40. Antengene Competitive Strengths & Weaknesses

Table 41. Genor BioPharma Co., Ltd. Basic Information, Area Served and Competitors

Table 42. Genor BioPharma Co., Ltd. Major Business

Table 43. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product and

Services

Table 44. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 45. Genor BioPharma Co., Ltd. Recent Developments/Updates

Table 46. Genor BioPharma Co., Ltd. Competitive Strengths & Weaknesses

Table 47. Hospira (Pfizer Inc.) Basic Information, Area Served and Competitors

Table 48. Hospira (Pfizer Inc.) Major Business

Table 49. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product and Services

Table 50. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Hospira (Pfizer Inc.) Recent Developments/Updates

Table 52. Hospira (Pfizer Inc.) Competitive Strengths & Weaknesses

Table 53. Dizal Pharma Basic Information, Area Served and Competitors

Table 54. Dizal Pharma Major Business

Table 55. Dizal Pharma Peripheral T-cell lymphoma Therapy Product and Services

Table 56. Dizal Pharma Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Dizal Pharma Recent Developments/Updates

Table 58. Dizal Pharma Competitive Strengths & Weaknesses

Table 59. Bristol-Myers Squibb Company Basic Information, Area Served and Competitors

Table 60. Bristol-Myers Squibb Company Major Business

Table 61. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product and Services

Table 62. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Bristol-Myers Squibb Company Recent Developments/Updates

Table 64. Bristol-Myers Squibb Company Competitive Strengths & Weaknesses

Table 65. Sigma-Tau Pharmaceuticals, Inc. Basic Information, Area Served and Competitors

Table 66. Sigma-Tau Pharmaceuticals, Inc. Major Business

Table 67. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services

Table 68. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Sigma-Tau Pharmaceuticals, Inc. Recent Developments/Updates

Table 70. Sigma-Tau Pharmaceuticals, Inc. Competitive Strengths & Weaknesses

Table 71. Pacira Pharmaceuticals, Inc. Basic Information, Area Served and Competitors

Table 72. Pacira Pharmaceuticals, Inc. Major Business
Table 73. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services
Table 74. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Pacira Pharmaceuticals, Inc. Recent Developments/Updates
Table 76. Pacira Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 77. Spectrum Pharmaceuticals, Inc. Basic Information, Area Served and Competitors
Table 78. Spectrum Pharmaceuticals, Inc. Major Business
Table 79. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product and Services
Table 80. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Spectrum Pharmaceuticals, Inc. Recent Developments/Updates
Table 82. Spectrum Pharmaceuticals, Inc. Competitive Strengths & Weaknesses
Table 83. Celgene Corporation Basic Information, Area Served and Competitors
Table 84. Celgene Corporation Major Business
Table 85. Celgene Corporation Peripheral T-cell lymphoma Therapy Product and Services
Table 86. Celgene Corporation Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Celgene Corporation Recent Developments/Updates
Table 88. Celgene Corporation Competitive Strengths & Weaknesses
Table 89. Eisai Co., Ltd. Basic Information, Area Served and Competitors
Table 90. Eisai Co., Ltd. Major Business
Table 91. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product and Services
Table 92. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Eisai Co., Ltd. Recent Developments/Updates
Table 94. Eisai Co., Ltd. Competitive Strengths & Weaknesses
Table 95. Leadiant Biosciences Basic Information, Area Served and Competitors
Table 96. Leadiant Biosciences Major Business
Table 97. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product and Services
Table 98. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Leadiant Biosciences Recent Developments/Updates
Table 100. Leadiant Biosciences Competitive Strengths & Weaknesses

Table 101. Merck Basic Information, Area Served and Competitors
Table 102. Merck Major Business
Table 103. Merck Peripheral T-cell lymphoma Therapy Product and Services
Table 104. Merck Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Merck Recent Developments/Updates
Table 106. Merck Competitive Strengths & Weaknesses
Table 107. Genmab AS Basic Information, Area Served and Competitors
Table 108. Genmab AS Major Business
Table 109. Genmab AS Peripheral T-cell lymphoma Therapy Product and Services
Table 110. Genmab AS Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Genmab AS Recent Developments/Updates
Table 112. HUYABIO International Basic Information, Area Served and Competitors
Table 113. HUYABIO International Major Business
Table 114. HUYABIO International Peripheral T-cell lymphoma Therapy Product and Services
Table 115. HUYABIO International Peripheral T-cell lymphoma Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 116. Global Key Players of Peripheral T-cell lymphoma Therapy Upstream (Raw Materials)
Table 117. Peripheral T-cell lymphoma Therapy Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Peripheral T-cell lymphoma Therapy Picture
- Figure 2. World Peripheral T-cell lymphoma Therapy Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Peripheral T-cell lymphoma Therapy Total Market Size (2018-2029) & (USD Million)
- Figure 4. World Peripheral T-cell lymphoma Therapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
- Figure 5. World Peripheral T-cell lymphoma Therapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)
- Figure 6. United States Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 7. China Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 8. Europe Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 9. Japan Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 10. South Korea Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 11. ASEAN Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 12. India Based Company Peripheral T-cell lymphoma Therapy Revenue (2018-2029) & (USD Million)
- Figure 13. Peripheral T-cell lymphoma Therapy Market Drivers
- Figure 14. Factors Affecting Demand
- Figure 15. World Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)
- Figure 16. World Peripheral T-cell lymphoma Therapy Consumption Value Market Share by Region (2018-2029)
- Figure 17. United States Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)
- Figure 18. China Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)
- Figure 19. Europe Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)

Figure 23. India Peripheral T-cell lymphoma Therapy Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Peripheral T-cell lymphoma Therapy by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Peripheral T-cell lymphoma Therapy Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Peripheral T-cell lymphoma Therapy Markets in 2022

Figure 27. United States VS China: Peripheral T-cell lymphoma Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Peripheral T-cell lymphoma Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Peripheral T-cell lymphoma Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Peripheral T-cell lymphoma Therapy Market Size Market Share by Type in 2022

Figure 31. Chidamide

Figure 32. Selinexor

Figure 33. Other

Figure 34. World Peripheral T-cell lymphoma Therapy Market Size Market Share by Type (2018-2029)

Figure 35. World Peripheral T-cell lymphoma Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 36. World Peripheral T-cell lymphoma Therapy Market Size Market Share by Application in 2022

Figure 37. Hospitals

Figure 38. Clinics

Figure 39. Peripheral T-cell lymphoma Therapy Industrial Chain

Figure 40. Methodology

Figure 41. Research Process and Data Source

I would like to order

Product name: Global Peripheral T-cell lymphoma Therapy Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G0D359A5AA67EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0D359A5AA67EN.html>